Suven Life Sciences Limited — Board Meeting, 16-07-2025: Outcome of Board Meeting

Suven Life Sciences' Board has approved the allotment of 91,86,490 new equity shares, resulting from the conversion of warrants. The company successfully raised Rs. 123.10 Cr from this issuance, with shares allotted at Rs. 134 each. Major non-promoter investors include QUANT MUTUAL FUND, ABAKKUS DIVERSIFIED ALPHA FUND, and COBRA INDIA (MAURITIUS) LIMITED. This capital infusion increases Suven's paid-up equity share capital to 22.73 Cr shares from 21.81 Cr shares, reflecting a strengthened financial position.